CD274 and non-small cell lung carcinoma: In fact, recent clinical trials like the phase III PACIFIC demonstrated that PD-L1 blockage with Durvalumab post-chemoradiation significantly improved overall and progression-free survival in unresectable stage III non-small cell lung cancer (NSCLC) [100].